[Retinal pigment epithelium--the point about safety of antimalarial agents].
The antimalarial agents Chloroquine and Hydroxychloroquine are used for the treatment of inflammatory disorders such as rheumatoid arthritis and lupus erythematosus. The first published reports of retinal toxicity appeared in 1959. Despite a low incidence for low doses and a short period of time, a regular ophthalmological screening is recommended to detect this maculopathy early. High risk criteria are: > 3 mg/kg/d of Chloroquine or > 6.5 mg/kg/d of Hydroxychloroquine, duration of treatment > 5 years, obesity, renal or hepatic disease, old age or pre-existing macular disease. Annual screening, and in some cases every 6 months, is recommended for high risk patients. Low risk patients will have an ophthalmologic examination every 18 months. The baseline examination includes visual acuity, Amsler grid, biomicroscopy, automated perimetry (central 10 degrees), color vision testing and fundus. Fluoroangiography and (multifocal) electroretinography should be considered if baseline screening is doubtfull or if toxicity is suspected. If relative paracentral bilateral scotomas or subtle alterations of retinal pigmentary epithelium are documented, the drug should be stopped. The collaboration with the internist and good information to the patient are necessary.
Vanheesbeke
A
A
Service d'Ophtalmologie, Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgique. anne.vanheesbeke@rhms.be
D000368:Aged; D000818:Animals; D000962:Antimalarials / Q000009:adverse effects* / Q000633:toxicity; D002738:Chloroquine / Q000009:adverse effects; D002945:Cisplatin / Q000009:adverse effects* / Q000633:toxicity; D006801:Humans; D006886:Hydroxychloroquine / Q000009:adverse effects; D008268:Macular Degeneration / Q000139:chemically induced* / Q000175:diagnosis; D010857:Pigment Epithelium of Eye / Q000187:drug effects*; D012307:Risk Factors; D015351:Vision Screening
D000962:Antimalarials; D006886:Hydroxychloroquine; D002738:Chloroquine; D002945:Cisplatin